IFN-γ's upregulation of PD-L1 supports the rationale for anti-PD-L1/PD-1 axis therapies in cancer therapy, but it also highlights why these therapies are only useful for a small portion of patients with high baseline levels of PD-L1 expression. This evidence concerns the gene CD274 and cancer.